The RabiesVaccine Market in Asia Pacific is expected to witness new entrants and is amajor competitive market due to the burden of rabies. According to datapublished by the World Health Organization (WHO) in 2017, India accounts for59.9% of deaths due to rabies in Asia, and 35% of deaths globally. Majorplayers operating in the region are Yisheng Biopharma, Serum Institute ofIndia, Zuventus, and Bharat Biotech Ltd. Moreover companies such as YishengLaboratories and CPL Laboratories (India) have vaccine candidates in clinicaltrials.
Rabies is a viral zoonoticdisease caused through a dog’s bite which leads to progressive and fatalinflammation of the brain and spinal cord. There are two type of rabies;furious rabies and paralytic rabies. Symptoms accompanied with furious rabiesare hyperactivity and hallucination. Paralytic rabies can cause coma andparalysis. Rabies seems fatal disease but it can be controlled through vaccinesand medicines which have long been available to prevent death by rabies.According World Health Organization (WHO), globally rabies cause fatalitiesnearly 10,000 people yearly and almost 99% cases are due to dog bites. Symptomscaused by rabies are wound, fever with pain near the wound, tingling, prickingat wound site, and if not treated properly it can lead to cardiac orrespiratory arrest. According to World Health Organization (WHO), in 2017,rabies caused 59,000 deaths annually in 150 countries with 95% cases in ruraldistricts.
Global Rabies Vaccines Market-Drivers
Key players are focused onresearch and development strategies which are expected to drive the globalrabies vaccine market growth during the forecast period. For instance, in 2017,CPL Laboratories (India), a joint venture biotechnology company established in2009 by Novavax Inc., USA and Cadila Pharmaceuticals Limited, stated that Nano-particle vaccine of baculvirous-derived glycoprotein, a four dose regimevaccine is in phase-3 human trial, and is expected to be approved by 2021.
In U.S., rabies in early 1960 to2000 was negligible, and witnessed a sudden rise resulting in 100 casesannually. Although the fatalities wererare, lack of awareness towards rabies is proving to be a risk. From 1960 to2018, 127 cases of rabies were reported in U.S. from dog bites and bat bites.Whereas in Asia, rabies is a major burden, accounting for almost 35,000 deaths,fatalities caused by rabies in India are 55%. In Africa, an estimated 21,476 human deaths occur due to dog bite rabies,Africa spends less on the post exposure prophylaxis treatment of rabies andhave highest mortality rate due to rabies. Central Asia and Middle East Asiahave an estimated 1875 and 229 fatalities yearly. These factors are is expectedto drive the global rabies vaccines market growth during the forecast period.
Global Rabies VaccinesMarket-Impact of COVID-19 Analysis on the Global Rabies Vaccine Market
The impact of COVID-19 on theglobal rabies vaccine market has affected every market around the globe in anegative way. As the world still struggles to recover from the COVID-19situation it will take a long time for every market to recover its losses.People have been reluctant to visit the physicians for vaccination due tosocial distancing. As per the situation, the impact of COVID-19 has stronglyaffected the future market opportunities, revenue growth graph, and the profitgains of the business for global rabies vaccine market.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/4005
Global Rabies Vaccines Market -Restraints
Emerging economies in Africa andAsia are expected to witness a major burden of rabies due to lack of awarenessand costly treatment. Post exposure, prophylaxis is a dose regime for dogmediated rabies. According to World Health Organization (WHO), in 2017, theestimated cost of PEP was US $1.5 million, which can make it unaffordable inmid- or low-income countries and restrain the growth of the global rabiesvaccines market during the forecast period.
Global Rabies Vaccine Market –Regional Analysis
Regional segmentation of theglobal rabies vaccine market includes North America, Latin America, Europe,Asia Pacific, Middle East, and Africa. North America is projected to dominatethe global rabies vaccines market with the largest share during the forecastperiod. The rising investments by governments in the public sector, as well asprograms to eradicate rabies are favouring growth of the market in the region.For instance, countries in North America in 2008 established the North AmericaRabies Management Plan, by assessing and defining the needs, priorities tocontrol rabies and eventually eliminate it from Canada, Mexico, and the U.S.
According to the European Centrefor Disease Prevention and Control, in 2014 only 3 cases of rabies werereported in Europe, whereas Europe being the highest vaccine manufacturer forrabies. Key market players in Europe are GlaxoSmithKline, Sanofi–Pasteur andNovartis AG.
Furthermore, the market in AsiaPacific is expected to witness significant growth owing to active involvementby manufacturers in Asia Pacific countries such as China, Japan and Indiaregarding development of innovative rabies vaccine and its substitutes. InFebruary 2018, BioNote, Inc., a South Korean veterinary diagnostic companyoperating in rabies diagnostics, announced the launch of a newimmune-fluorescent device, Vcheck, which can measure diagnostic result valueswith the help of fluorescent materials which help in detecting the zoonoticdisease in animals.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/rabies-vaccine-market-4005
Global Rabies Vaccine Market-Competitive Landscape
Key players operating in globalrabies vaccine market are Sanofi S.A., Novartis International AG, SerumInstitute of India Pvt. Ltd, Indian Immunologicals Limited, Bharat Biotech Ltd,Zuventus HealthCare Ltd., Cpl Biologicals Private Limited, Yisheng BiopharmaCo., Ltd, GlaxoSmithKline plc, Bavarian Nordic A/S, and Chiron Behring VaccinesPrivate Limited.
Key Developments-
In 2016, Serum Institute ofIndia, developed new rabies vaccine, RABIVAS-S, for countries with highestburden of rabies.
The World Organization for AnimalHealth (OIE), a vaccine bank, was established in 2012 with production order forrabies vaccine of 50,000 doses in 31st December 2016. The OIE recorded 16million doses of vaccines in 24 countries for pre- and post-exposureprophylaxis treatment for rabies.
In 2019, Yisheng Biopharma(Singapore) Pte Ltd stated that development of adjuvant rabies vaccine, PIKAwhich is composed of RABIPUR and polyisonic-polycytidcyclic acid, has completedits phase 2 clinical trial.
In 2019, GlaxoSmithKline divestedits rabies and tick-borne vaccine to Bavarian Nordic, and incurred payment of$36 million from Bavarian Nordic.
In 2019, Asian subsidiary ofGlaxoSmithKline divested its Chiron Behring Vaccines unit in Gujarat, India todomestic clinical biotechnology company, Bharat Biotech.
In 2019, Wuhan Institute ofVirology announced positive results of a novel rabies vaccine in pre-clinicaltest. The novel vaccine is a live attenuated vaccine; VEEV-RABV-G.
In June 18, 2020 Bavarian NordicA/S and Valneva SE announced a partnership for marketing and distribution ofrabies and tick-borne vaccines in selected European countries and Canada.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/4005
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
